161 related articles for article (PubMed ID: 36703271)
1. Botulinum toxin injection for refractory Raynaud phenomenon and digital ulcers in systemic sclerosis.
Shen YH; Lee YH; Leong PY
Int J Rheum Dis; 2023 Feb; 26(2):187-189. PubMed ID: 36703271
[No Abstract] [Full Text] [Related]
2. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
3. Raynaud, digital ulcers and calcinosis in scleroderma.
Nitsche A
Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
Ennis D; Ahmad Z; Anderson MA; Johnson SR
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
[TBL] [Abstract][Full Text] [Related]
5. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
6. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
8. Effects of botulinum toxin injection on systemic sclerosis-related digital ulcers.
Souk JW; Kim HS
Korean J Intern Med; 2019 Sep; 34(5):1169-1170. PubMed ID: 30099864
[No Abstract] [Full Text] [Related]
9. Digit Ulcerations in a Young Woman.
Varghese B; Chew E; Konig MF
JAMA; 2020 Jul; 324(4):385-386. PubMed ID: 32568390
[No Abstract] [Full Text] [Related]
10. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
[TBL] [Abstract][Full Text] [Related]
11. Raynaud phenomenon and digital ulcers in systemic sclerosis.
Hughes M; Allanore Y; Chung L; Pauling JD; Denton CP; Matucci-Cerinic M
Nat Rev Rheumatol; 2020 Apr; 16(4):208-221. PubMed ID: 32099191
[TBL] [Abstract][Full Text] [Related]
12. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
[TBL] [Abstract][Full Text] [Related]
13. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Gore J; Silver R
Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
[No Abstract] [Full Text] [Related]
14. Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment.
Frech TM; Machin DR; Murtaugh MA; Stoddard GJ; Bloom SI; Phibbs JV; Donato AJ
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):175-182. PubMed ID: 30277867
[TBL] [Abstract][Full Text] [Related]
15. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.
Herrgott I; Riemekasten G; Hunzelmann N; Sunderkötter C
Rheumatol Int; 2008 Aug; 28(10):1023-9. PubMed ID: 18320192
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review.
Cai R; Yi Z; Li T; Mu R
Chin Med J (Engl); 2022 May; 135(9):1133-1134. PubMed ID: 35773968
[No Abstract] [Full Text] [Related]
17. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.
Yin H; Liu B; Li Q; Yan Q; Lu L
Arthritis Rheumatol; 2023 Mar; 75(3):486. PubMed ID: 36209513
[No Abstract] [Full Text] [Related]
18. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
Kassamali B; Desai S; Min M; Mazori D; Villa-Ruiz C; Kus K; Cobos G; Merola J; LaChance A; Vleugels R
J Drugs Dermatol; 2021 Nov; 20(11):1257-1259. PubMed ID: 34784129
[TBL] [Abstract][Full Text] [Related]
19. [Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis].
Nielsen JB; Hvid L; Olesen AB
Ugeskr Laeger; 2014 Feb; 176(8A):V08130527. PubMed ID: 25350310
[TBL] [Abstract][Full Text] [Related]
20. Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial.
Lee KA; Park S; Kim BY; Kim YS; Ju JH; Son CN; Kim SH; Kim HS
J Clin Rheumatol; 2021 Dec; 27(8):e599-e601. PubMed ID: 33448749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
